Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC

Clinical trial NCT07197580 · RECRUITING

Trial details

NCT number: NCT07197580
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

ccRCC Renal Cell Carcinoma (Kidney Cancer)Renal Cell Carcinoma (RCC)Renal Cell Cancer Metastatic Renal Cell Cancer, Recurrent Clear Cell Renal Cell Cancer (ccRCC)

Start date: 2026-03-25
Primary completion: 2027-08-31
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.